Shanghai Yizhong Pharmaceutical Co., Ltd.
SHH: 688091.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Jingsong Zhou
- Employees
- 375
- Headquarters
- Shanghai, China
- IPO year
- 2021
- Market cap
- CN¥12.5B
- Website
- https://www.yizhongpharma.com
Loading 688091…
Loading profile data…Frequently asked questions about 688091
What does Shanghai Yizhong Pharmaceutical Co., Ltd. (688091.SS) do?
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It develops a dosage form of paclitaxel, an anti-tumor chemotherapeutic. The company was founded in 2009 and is based in Shanghai, China.
Where does 688091.SS trade?
Shanghai Yizhong Pharmaceutical Co., Ltd. (688091.SS) trades on the Shanghai Stock Exchange.
What sector is 688091.SS in?
Shanghai Yizhong Pharmaceutical Co., Ltd. (688091.SS) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Shanghai Yizhong Pharmaceutical Co., Ltd.?
Jingsong Zhou is the chief executive officer of Shanghai Yizhong Pharmaceutical Co., Ltd. (688091.SS).
Where is Shanghai Yizhong Pharmaceutical Co., Ltd. headquartered?
Shanghai Yizhong Pharmaceutical Co., Ltd. is headquartered in China.
Does 688091.SS pay a dividend?
Yes — Shanghai Yizhong Pharmaceutical Co., Ltd. (688091.SS) paid a trailing twelve-month dividend of CNY 0.31 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 688091.SS go public?
Shanghai Yizhong Pharmaceutical Co., Ltd. (688091.SS) completed its initial public offering in 2021.